In lung cancer, Bruno et al. showed that activated TIL-Bs could present antigens to CD4+ TIL-Ts and induce effector T-cell responses61, supportive of TIL-B’s antitumor activity in LUAD. This evidence concerns the gene CD4 and lung carcinoma.